Sotrovimab News and Research

RSS
Study analyzes antigenic properties of SARS-CoV-2 Omicron sublineages

Study analyzes antigenic properties of SARS-CoV-2 Omicron sublineages

Neutralizing antibody ABP-310 found to be highly potent against SARS-CoV-2 variants including Omicron

Neutralizing antibody ABP-310 found to be highly potent against SARS-CoV-2 variants including Omicron

Omicron resists antibodies, causes less severe disease than previous SARS-CoV-2variants

Omicron resists antibodies, causes less severe disease than previous SARS-CoV-2variants

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

UK's most vulnerable will soon be able to access second ground-breaking antiviral

UK's most vulnerable will soon be able to access second ground-breaking antiviral

Study explores vaccine effectiveness against the SARS-CoV-2 Omicron variant in patients receiving hemodialysis

Study explores vaccine effectiveness against the SARS-CoV-2 Omicron variant in patients receiving hemodialysis

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

Exploring receptor-blocking conserved non-neutralizing antibodies for SARS-CoV-2 therapy

Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infection

Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infection

Patient, beware: Some states still pushing ineffective covid antibody treatments

Patient, beware: Some states still pushing ineffective covid antibody treatments

Researchers report isolation of potently neutralizing antibodies against  highly transmissible SARS-CoV-2 variants

Researchers report isolation of potently neutralizing antibodies against highly transmissible SARS-CoV-2 variants

WHO's recommendation provides two new options for treating COVID-19

WHO's recommendation provides two new options for treating COVID-19

SARS-CoV-2 Omicron variant's infectivity, vaccine breakthrough, and antibody resistance

SARS-CoV-2 Omicron variant's infectivity, vaccine breakthrough, and antibody resistance

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

Bolstering current therapeutic antibody treatments to help fight Omicron infections

Bolstering current therapeutic antibody treatments to help fight Omicron infections

Researchers create new monoclonal antibody treatment effective against both Delta and Omicron

Researchers create new monoclonal antibody treatment effective against both Delta and Omicron

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

Researchers discover antibodies that neutralize omicron and other SARS-CoV-2 variants

Researchers discover antibodies that neutralize omicron and other SARS-CoV-2 variants